Toronto, Canada - July 23, 2003 - VisualSonics is pleased to announce the addition of Dr. Sanjiv (Sam) Gambhir to their Scientific Advisory Board (SAB).
Dr. Gambhir has recently been appointed as Director of the Stanford School of Medicine Program in Molecular Imaging. He is a Professor of Radiology and Head of the Division of Nuclear Medicine. Most recently, Dr. Gambhir was also Director of the Crump Institute for Molecular Imaging, UCLA. Dr. Gambhir is a recognized world leader in the area of imaging approaches to Gene Therapy. His research interests include the development of techniques to study various molecular/biochemical events taking place in living animals and humans, in their natural state, at the cellular and sub-cellular levels. He holds a B.S. in Physics from Arizona State University and a Ph.D. in Biomathematics and M.D. from UCLA. Dr. Gambhir has remained at UCLA following his education first as an Assistant Professor in the Department of Molecular & Medical Pharmacology. He also held the position, Director of the Computational & Communication Sciences Division and was the Principle Investigator for the DOE Laboratory of Structural Biology and Molecular Medicine. His most recent research focus is on the imaging approaches to gene therapy, developing imaging assays to monitor fundamental cellular events in living subjects. His accomplishments include over 60 published papers and he has been lauded with awards both nationally and internationally.
"The addition of Dr. Gambhir to our Scientific Advisory Board will compliment our current Board expertise and will assist in continuing to expand the utility of our Vevo 660™ high-resolution imaging system to the small animal researcher", says Tom Little, CEO of VisualSonics. "With Dr. Gambhir's innovative and leading work in the areas of molecular imaging and multi-modality approaches to imaging, we are excited about the ability to make our Vevo 660™ high-resolution ultrasound system even more pervasive and flexible as an imaging tool".
"As the widespread use of imaging technology continues to grow in phenotypic study, it becomes increasingly important to unify the early detection of molecular events with later stage physiological and anatomical changes", says Dr. Gambhir. "The VisualSonics high-resolution ultrasound technology is a strong compliment to this multi-modality approach, especially in terms of its ability to visualize and measure anatomic and hemodynamics in vivo in small animals. The possibility of also adapting the VisualSonics technology for imaging molecular events should further expand the role of this exciting technology".
Dr. Gambhir joins the current members of the VisualSonics Scientific Advisory Board which include:
- Dr. F. Stuart Foster, Professor and Associate Chair, Ph.D., Department of Medical Biophysics, University of Toronto, Chief Technical Officer and Chairman, VisualSonics;
- Dr. S. Lee Adamson, Ph.D. Director, CMHD Mouse Physiology Lab, Senior Scientist, Samuel Lunenfeld Research Institute, Professor, Obstetrics & Gynecology, University of Toronto, Mount Sinai Hospital, Toronto, ON;
- Dr. Daniel H Turnbull, Associate Professor of Radiology and Pathology, Director, Mouse Imaging Facility, Skirball Institute of Biomolecular Medicine and NYU Cancer Institute, New York University School of Medicine.
About VisualSonics
VisualSonics (www.visualsonics.com) is the leading manufacturer of high-resolution in vivo imaging systems for small animal research. VisualSonics' Vevo 660™ high-resolution imaging system provides real-time visualization and measurement of anatomical and hemodynamic function in small animals down to 30 microns. Because of the non-invasive nature of the technology, longitudinal studies of the same animal can be performed. This high-resolution imaging technology is being successfully applied to phenotypic-based research applications such as developmental biology, cardiovascular research, cancer biology, neurobiology and drug discovery.